Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 1.23 is 27% below its 5-year average of 1.69, near the low end of its 5-year range (0.79–16.16).
As of the fiscal period ended Tuesday, June 30, 2026. 13.23% above its 12-month average of 1.09.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 1.23.
QUICK RATIO (ACID-TEST)
1.23
QUICK RATIO (ACID-TEST) AVG TTM
1.09
QUICK RATIO (ACID-TEST) AVG 3Y
1.34
QUICK RATIO (ACID-TEST) AVG 5Y
1.69
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
+13.23%
CURRENT VS 3Y AVG
-8.18%
CURRENT VS 5Y AVG
-27.14%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.26
median of 790 covered companies
CURRENT VS SECTOR MEDIAN
-62.27%
vs the sector median at left
NervGen Pharma Corp. Common stock
Market Cap
$149.18M
Quick Ratio (Acid-Test)
1.23
TTM Avg
1.09
3Y Avg
1.34
5Y Avg
1.69
Market Cap
$148.31M
Quick Ratio (Acid-Test)
0.84
TTM Avg
0.97
3Y Avg
0.83
5Y Avg
1.00
Market Cap
$146.88M
Quick Ratio (Acid-Test)
15.62
TTM Avg
10.23
3Y Avg
11.93
5Y Avg
11.24
Market Cap
$146.98M
Quick Ratio (Acid-Test)
2.47
TTM Avg
5.26
3Y Avg
13.15
5Y Avg
16.36
Market Cap
$151.65M
Quick Ratio (Acid-Test)
2.99
TTM Avg
3.92
3Y Avg
3.42
5Y Avg
4.30
Market Cap
$151.58M
Quick Ratio (Acid-Test)
5.55
TTM Avg
4.34
3Y Avg
4.83
5Y Avg
5.44
Market Cap
$152.73M
Quick Ratio (Acid-Test)
9.71
TTM Avg
4.67
3Y Avg
6.04
5Y Avg
19.74
Market Cap
$144.19M
Quick Ratio (Acid-Test)
0.82
TTM Avg
5.49
3Y Avg
4.19
5Y Avg
4.19
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NervGen Pharma Corp. Common stock (NGEN) | $149.18M | 1.23 | 1.09 | 1.34 | 1.69 |
| LifeMD, Inc. (LFMDP)vs › | $148.31M | 0.84 | 0.97 | 0.83 | 1.00 |
| Anavex Life Sciences Corp. (AVXL)vs › | $146.88M | 15.62 | 10.23 | 11.93 | 11.24 |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $146.98M | 2.47 | 5.26 | 13.15 | 16.36 |
| Codexis, Inc. (CDXS)vs › | $151.65M | 2.99 | 3.92 | 3.42 | 4.30 |
| Cardiol Therapeutics Inc. (CRDL)vs › | $151.58M | 5.55 | 4.34 | 4.83 | 5.44 |
| ALX Oncology Holdings Inc. (ALXO)vs › | $152.73M | 9.71 | 4.67 | 6.04 | 19.74 |
| Korsana Biosciences, Inc. (KRSA)vs › | $144.19M | 0.82 | 5.49 | 4.19 | 4.19 |
| Nyxoah S.A. (NYXH)vs › | $144.10M | 2.31 | 2.75 | 4.17 | 7.24 |
| Immuneering Corporation (IMRX)vs › | $142.31M | 19.47 | 11.39 | 11.91 | 15.23 |
Quick Ratio
1.23
Excludes inventory
Current Ratio
1.23
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 1.23 |
| 2026-03-31 | 1.34 |
| 2025-12-31 | 1.16 |
| 2025-09-30 | 0.79 |
| 2025-06-30 | 0.92 |
| 2025-03-31 | 1.06 |
| 2024-12-31 | 1.12 |
| 2024-09-30 | 1.66 |
| 2024-06-30 | 1.78 |
| 2024-03-31 | 2.42 |
| 2023-12-31 | 0.83 |
| 2023-09-30 | 1.40 |
| 2023-06-30 | 1.73 |
| 2023-03-31 | 2.04 |
| 2022-12-31 | 2.27 |
| 2022-09-30 | 2.74 |
| 2022-06-30 | 4.25 |
| 2022-03-31 | 11.99 |
| 2021-12-31 | 16.16 |
| 2021-09-30 | 8.20 |
| 2021-06-30 | 8.11 |
| 2021-03-31 | 5.04 |
| 2020-12-31 | 8.21 |
| 2020-09-30 | 30.19 |
| 2020-06-30 | 10.29 |
| 2020-03-31 | 6.77 |
| 2019-12-31 | 6.77 |
| 2019-09-30 | 11.40 |
| 2019-06-30 | 25.72 |
| 2019-03-31 | 19.43 |
| 2018-12-31 | 5.68 |
| 2018-09-30 | 9.28 |
| 2018-06-30 | 3.15 |
| 2018-03-31 | 0.00 |
| 2017-12-31 | 0.00 |
